The RNA editing for neurodegenerative diseases market is witnessing rapid growth as researchers develop precise RNA-based therapies for Alzheimer’s, Parkinson’s, and other disorders. These treatments offer targeted interventions without permanent DNA changes. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: RNA Editing for Neurodegenerative Diseases Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. RNA Editing for Neurodegenerative Diseases Market, by Editing Modality
8.1.1. ADAR-Mediated RNA Base Editing
8.1.1.1. Market Revenue and Forecast
8.1.2. RNA Exon Editing / Trans-Splicing
8.1.2.1. Market Revenue and Forecast
8.1.3. Programmable Oligonucleotide Editors
8.1.3.1. Market Revenue and Forecast
8.1.4. RNA-Guided Deaminases & Engineered Editing Enzymes
8.1.4.1. Market Revenue and Forecast
8.1.5. Transient Knockdown + Reprogramming Approaches
8.1.5.1. Market Revenue and Forecast
9.1. RNA Editing for Neurodegenerative Diseases Market, by Target Neurodegenerative Disease
9.1.1. Alzheimer’s Disease
9.1.1.1. Market Revenue and Forecast
9.1.2. Parkinson’s Disease
9.1.2.1. Market Revenue and Forecast
9.1.3. Huntington’s Disease
9.1.3.1. Market Revenue and Forecast
9.1.4. Amyotrophic Lateral Sclerosis (ALS)
9.1.4.1. Market Revenue and Forecast
9.1.5. Frontotemporal Dementia (FTD)
9.1.5.1. Market Revenue and Forecast
9.1.6. Spinocerebellar Ataxias & Other Rare CNS Disorders
9.1.6.1. Market Revenue and Forecast
10.1. RNA Editing for Neurodegenerative Diseases Market, by Product Type
10.1.1. Single-Molecule RNA Editors (Synthetic Oligonucleotides)
10.1.1.1. Market Revenue and Forecast
10.1.2. Vector-Encoded RNA Editors (AAV / LV Platforms)
10.1.2.1. Market Revenue and Forecast
10.1.3. Programmable RNA-Guided Editors (Engineered Deaminases)
10.1.3.1. Market Revenue and Forecast
10.1.4. Platform-Licensed Editing Programs
10.1.4.1. Market Revenue and Forecast
11.1. RNA Editing for Neurodegenerative Diseases Market, by End-User
11.1.1. Large Biopharmaceutical Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. RNA Editing Biotech Startups
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic Research Institutions
11.1.3.1. Market Revenue and Forecast
11.1.4. Contract Research Organizations (CROs)
11.1.4.1. Market Revenue and Forecast
11.1.5. Specialized Neurology Clinics & Hospitals
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Editing Modality
12.1.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.1.3. Market Revenue and Forecast, by Product Type
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Editing Modality
12.1.5.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.1.5.3. Market Revenue and Forecast, by Product Type
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Editing Modality
12.1.6.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.1.6.3. Market Revenue and Forecast, by Product Type
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Editing Modality
12.2.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.2.3. Market Revenue and Forecast, by Product Type
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Editing Modality
12.2.5.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.2.5.3. Market Revenue and Forecast, by Product Type
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Editing Modality
12.2.6.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.2.6.3. Market Revenue and Forecast, by Product Type
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Editing Modality
12.2.7.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.2.7.3. Market Revenue and Forecast, by Product Type
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Editing Modality
12.2.8.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.2.8.3. Market Revenue and Forecast, by Product Type
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Editing Modality
12.3.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.3.3. Market Revenue and Forecast, by Product Type
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Editing Modality
12.3.5.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.3.5.3. Market Revenue and Forecast, by Product Type
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Editing Modality
12.3.6.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.3.6.3. Market Revenue and Forecast, by Product Type
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Editing Modality
12.3.7.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.3.7.3. Market Revenue and Forecast, by Product Type
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Editing Modality
12.3.8.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.3.8.3. Market Revenue and Forecast, by Product Type
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Editing Modality
12.4.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.4.3. Market Revenue and Forecast, by Product Type
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Editing Modality
12.4.5.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.4.5.3. Market Revenue and Forecast, by Product Type
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Editing Modality
12.4.6.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.4.6.3. Market Revenue and Forecast, by Product Type
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Editing Modality
12.4.7.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.4.7.3. Market Revenue and Forecast, by Product Type
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Editing Modality
12.4.8.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.4.8.3. Market Revenue and Forecast, by Product Type
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Editing Modality
12.5.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.5.3. Market Revenue and Forecast, by Product Type
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Editing Modality
12.5.5.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.5.5.3. Market Revenue and Forecast, by Product Type
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Editing Modality
12.5.6.2. Market Revenue and Forecast, by Target Neurodegenerative Disease
12.5.6.3. Market Revenue and Forecast, by Product Type
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. ADARx Pharmaceuticals
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Amber Bio
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Ascidian Therapeutics
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Beam Therapeutics
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Eli Lilly & Co. (via Prevail Therapeutics)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. GSK Plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Korro Bio
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Moderna Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. ProQR Therapeutics
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Roche Holding AG
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description